Him & Hers，WWW对Novo试图限制复合索马鲁肽的尝试表示不满

2024-10-24 03:49

Hims & Hers Health (NYSE:HIMS) and WW International (NASDAQ:WW) are both down significantly in Wednesday trading following Novo Nordisk's (NVO) attempt to get the U.S. FDA to ban the manufacture of compounded semaglutide.
The Danish drugmaker has asked the agency to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that compounded versions pose safety risks. Semaglutide is a blockbuster med for Novo and is the active ingredient in its weight loss and type 2 diabetes drugs, Wegovy and Ozempic.
Earlier this year, Him and Hers and WW International said they would offer compounded version of semaglutide at a fraction of the cost of the brand-name versions.
This was permissible as Novo has been experiencing a shortage of semaglutide for much of the year. However, that has now ended.
Novo rival Eli Lilly (LLY) recently sued three compounders for continuing to make and sell compounded tirzepatide, the active ingredient in its weight loss and diabetes meds Zepbound and Mounjaro.
Hims & Hers is down ~11%, while WW is down ~7%.

More on Hims & Hers Health, WW International